Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
Exelixis Stock Price (Quote) NASDAQ:EXEL
$20.82 ( 0.14% ) Thursday, 30th Jun 2022
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $17.37 | $22.45 | Thursday, 30th Jun 2022 EXEL stock ended at $20.82. This is 0.14% more than the trading day before Wednesday, 29th Jun 2022. During the day the stock fluctuated 2.73% from a day low at $20.48 to a day high of $21.04. |
| 90 days | $16.37 | $23.40 | |
| 52 weeks | $15.50 | $23.40 |
Historical Exelixis prices
| Date | Open | High | Low | Close | Volume |
| 2022-06-30 | $20.70 | $21.04 | $20.48 | $20.82 | 2 569 806 |
| 2022-06-29 | $21.00 | $21.11 | $20.67 | $20.79 | 3 294 282 |
| 2022-06-28 | $22.27 | $22.28 | $20.56 | $20.94 | 3 040 546 |
| 2022-06-27 | $22.13 | $22.39 | $21.81 | $22.22 | 2 148 274 |
| 2022-06-24 | $21.73 | $22.45 | $21.56 | $22.22 | 4 099 356 |
| 2022-06-23 | $20.24 | $21.36 | $20.20 | $21.33 | 2 434 327 |
| 2022-06-22 | $19.28 | $20.34 | $19.28 | $20.19 | 2 802 143 |
| 2022-06-21 | $18.71 | $19.51 | $18.52 | $19.35 | 2 960 189 |
| 2022-06-17 | $17.71 | $18.71 | $17.58 | $18.56 | 8 991 763 |
| 2022-06-16 | $17.63 | $17.81 | $17.42 | $17.57 | 1 656 737 |
| 2022-06-15 | $17.71 | $18.13 | $17.61 | $17.94 | 4 681 879 |
| 2022-06-14 | $17.79 | $17.80 | $17.37 | $17.67 | 1 411 196 |
| 2022-06-13 | $17.77 | $18.03 | $17.50 | $17.63 | 3 905 369 |
| 2022-06-10 | $18.38 | $18.78 | $18.04 | $18.14 | 1 944 526 |
| 2022-06-09 | $19.16 | $19.26 | $18.86 | $18.88 | 1 729 082 |
| 2022-06-08 | $19.44 | $19.52 | $19.16 | $19.22 | 1 181 242 |
| 2022-06-07 | $19.00 | $19.50 | $18.71 | $19.47 | 2 569 020 |
| 2022-06-06 | $19.18 | $19.26 | $18.63 | $18.78 | 1 543 271 |
| 2022-06-03 | $18.63 | $19.07 | $18.62 | $19.04 | 1 729 199 |
| 2022-06-02 | $18.29 | $18.65 | $18.00 | $18.59 | 1 404 569 |
| 2022-06-01 | $18.23 | $18.69 | $18.01 | $18.47 | 2 796 414 |
| 2022-05-31 | $18.36 | $18.46 | $18.04 | $18.33 | 2 653 849 |
| 2022-05-27 | $18.22 | $18.52 | $18.00 | $18.40 | 2 026 362 |
| 2022-05-26 | $17.78 | $18.59 | $17.70 | $18.19 | 3 087 426 |
| 2022-05-25 | $17.71 | $17.92 | $17.53 | $17.81 | 5 438 261 |
| 2022-05-24 | $17.61 | $17.83 | $17.49 | $17.70 | 2 676 599 |
| 2022-05-23 | $18.01 | $18.59 | $17.67 | $17.75 | 2 709 124 |
| 2022-05-20 | $17.56 | $17.80 | $17.17 | $17.76 | 4 517 700 |
| 2022-05-19 | $19.41 | $19.48 | $16.37 | $17.44 | 15 702 031 |
| 2022-05-18 | $20.46 | $20.73 | $19.45 | $19.49 | 4 493 826 |
| 2022-05-17 | $20.44 | $20.75 | $20.15 | $20.69 | 2 760 356 |
| 2022-05-16 | $20.00 | $20.50 | $19.93 | $20.26 | 1 620 050 |
| 2022-05-13 | $20.00 | $20.20 | $19.87 | $20.08 | 2 300 060 |
| 2022-05-12 | $19.66 | $20.01 | $19.39 | $19.80 | 3 747 696 |
| 2022-05-11 | $19.21 | $20.61 | $19.01 | $19.84 | 3 608 370 |
| 2022-05-10 | $20.00 | $20.15 | $19.62 | $19.77 | 5 159 757 |
| 2022-05-09 | $21.28 | $21.28 | $19.21 | $19.34 | 4 645 055 |
| 2022-05-06 | $21.97 | $22.08 | $21.19 | $21.49 | 2 488 169 |
| 2022-05-05 | $22.90 | $22.92 | $22.10 | $22.29 | 1 685 203 |
| 2022-05-04 | $22.63 | $22.90 | $22.10 | $22.83 | 2 302 463 |
| 2022-05-03 | $22.68 | $23.03 | $22.53 | $22.58 | 1 508 697 |
| 2022-05-02 | $22.21 | $22.68 | $22.01 | $22.66 | 3 189 986 |
| 2022-04-29 | $22.75 | $23.13 | $22.32 | $22.34 | 2 692 029 |
| 2022-04-28 | $22.65 | $22.82 | $22.11 | $22.77 | 1 613 478 |
| 2022-04-27 | $22.48 | $22.88 | $22.30 | $22.60 | 1 783 066 |
| 2022-04-26 | $22.74 | $22.84 | $22.14 | $22.25 | 1 484 728 |
| 2022-04-25 | $22.36 | $22.88 | $22.17 | $22.84 | 1 844 590 |
| 2022-04-22 | $22.42 | $22.78 | $22.24 | $22.42 | 638 922 |
| 2022-04-21 | $23.01 | $23.26 | $22.51 | $22.56 | 1 210 400 |
| 2022-04-20 | $22.86 | $23.04 | $22.44 | $22.99 | 1 729 000 |
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. It focuses on advancing cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development pr... ![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
